Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Epilepsy

Neonatal seizures still lack safe and effective treatment

Seizures after neonatal hypoxia are difficult to treat. A recent antiepileptic safety and dose-finding study examined phenobarbital plus bumetanide, but was stopped owing to apparent futility and increased risk of hearing loss. However, this decision could have been overcautious: 0.2 mg/kg bumetanide reduced seizure burden, and might not have increased hearing loss.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Miller, S. P. et al. Seizure-associated brain injury in term newborns with perinatal asphyxia. Neurology 58, 542–548 (2002).

    Article  CAS  Google Scholar 

  2. van Rooij, L. G., van den Broek, M. P., Rademaker, C. M. & de Vries, L. S. Clinical management of seizures in newborns: diagnosis and treatment. Paediatr. Drugs 15, 9–18 (2013).

    Article  Google Scholar 

  3. Pressler, R. M. et al. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol. 14, 469–477 (2015).

    Article  CAS  Google Scholar 

  4. Bittigau, P. et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc. Natl Acad. Sci. USA 99, 15089–15094 (2002).

    Article  CAS  Google Scholar 

  5. Cleary, R. T. et al. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS ONE 8, e57148 (2013).

    Article  CAS  Google Scholar 

  6. Sullivan, J. E., Witte, M. K., Yamashita, T. S., Myers, C. M. & Blumer, J. L. Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants. Clin. Pharmacol. Ther. 60, 424–434 (1996).

    Article  CAS  Google Scholar 

  7. Zohar, S. & O'Quigley, J. Optimal designs for estimating the most successful dose. Stat. Med. 30, 4311–4320 (2006).

    Article  Google Scholar 

  8. Bennet, L., Dean, J. M., Wassink, G. & Gunn, A. J. Differential effects of hypothermia on early and late epileptiform events after severe hypoxia in preterm fetal sheep. J. Neurophysiol. 97, 572–578 (2006).

    Article  Google Scholar 

  9. Smit, E. et al. Factors associated with permanent hearing impairment in infants treated with therapeutic hypothermia. J. Pediatr. 163, 995–1000 (2013).

    Article  Google Scholar 

  10. Wood, T. & Thoresen, M. Physiological responses to hypothermia. Semin. Fetal Neonatal Med. 20, 87–96 (2015).

    Article  Google Scholar 

Download references

Acknowledgements

We thank L. Walløe for help with assessing the statistical methods used in the trial. We thank the Norwegian and German Research Councils for their support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marianne Thoresen.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thoresen, M., Sabir, H. Neonatal seizures still lack safe and effective treatment. Nat Rev Neurol 11, 311–312 (2015). https://doi.org/10.1038/nrneurol.2015.74

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2015.74

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing